Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of TDF for Prevention of HIV
NCT00122512Phase 2Terminated
- Sponsor
- FHI 360
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by FHI 360. Primary endpoint: Extended safety of TDF 300mg daily. Status: terminated.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00122512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122512.